Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05949580 · ClinicalTrials.gov registry record
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- 500
- Enrollment target
- 5
- Study locations
NCT05949580: Recruiting study of Relapsing Remitting Multiple Sclerosis, sponsored by Hoffmann-La Roche.
NCT05949580 is a study of Relapsing Remitting Multiple Sclerosis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 500 participants, above the 183-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (173% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05949580, a study of Relapsing Remitting Multiple Sclerosis, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS (pwMS) in clinical practice. This is a two-year prospective data collection study with additional data collection at baseline evaluating medical practice over a period of at least one year before the introduction of the MS care management platform.
Conditions Studied
Interventions
- DEVICE MS Care Platform (icobrain ms and icompanion ms)
Study Locations (5)
New Jersey
- Hackensack University Medical Center - Hackensack
- Jersey Shore University Medical Centre - Neptune City
Other
- Universitaetsklinikum Carl Gustav Carus an der TU Dresden - Dresden
- Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim - Sinsheim
Minnesota
- Minneapolis Clinic of Neurology - Golden Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2028-03-31 |
What NCT05949580 shows while recruiting
NCT05949580 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 183-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (173% higher).
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which MS Care Platform (icobrain ms and icompanion ms) is the first listed.
NCT05949580 lists 5 locations in 3 states (New Jersey, Other, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05949580 about?
NCT05949580 is a clinical study titled "Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis". The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS (pwMS) in clinical practice. This is a two-year prospective data collection study with additional data collection at baseline...
What is the current status of trial NCT05949580?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-10-21. Estimated completion is 2028-03-31.
What conditions does trial NCT05949580 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT05949580?
The interventions under investigation include: MS Care Platform (icobrain ms and icompanion ms) (DEVICE).
Who is sponsoring clinical trial NCT05949580?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05949580 being conducted?
This trial has 5 study locations across Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05949580's enrollment target sits among peer trials
500 4th of 25 higher than 22 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
-
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI